Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

Interferon gamma-1b - Horizon Therapeutics plc

Drug Profile

Interferon gamma-1b - Horizon Therapeutics plc

Alternative Names: Actimmune; IFNγ-1b; Imukin; Interferon-gamma-1b

Latest Information Update: 08 Jul 2019

Price : $50 *
  • Adis is an information provider. We do not sell or distribute actual drugs.
  • Final gross price and currency may vary according to local VAT and billing address.
  • Your purchase entitles you to full access to the information contained in our drug profile at the time of purchase.
  • A link to download a PDF version of the drug profile will be included in your email receipt.

At a glance

  • Originator Genentech
  • Developer Fox Chase Cancer Center; Friedreichs Ataxia Research Alliance; Horizon Pharma; Horizon Therapeutics plc; InterMune
  • Class Antineoplastics; Antivirals; Interferons; Lymphokines
  • Mechanism of Action Interferon gamma stimulants
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    Yes - Chronic granulomatous disease; Pulmonary fibrosis; Friedreich's ataxia; Osteopetrosis; Renal cell carcinoma
  • New Molecular Entity No

Highest Development Phases

  • Marketed Chronic granulomatous disease; Osteopetrosis
  • Phase I/II Breast cancer
  • No development reported Hepatitis B; Hepatitis C; Solid tumours
  • Discontinued Atopic dermatitis; Cryptococcosis; Friedreich's ataxia; Hepatic fibrosis; Keloids; Mycoses; Non-Hodgkin's lymphoma; Ovarian cancer; Pulmonary fibrosis; Renal cell carcinoma; Systemic scleroderma; Tuberculosis

Most Recent Events

  • 02 May 2019 Horizon Pharma is now called Horizon Therapeutics plc
  • 11 Apr 2019 Los Angeles Biomedical Research Institute in collaboration with University of Minnesota and Horizon Pharma completes a phase II trial in Osteopetrosis (In children, In adolescents, In adults, In the elderly) (NCT02666768)
  • 28 Jan 2019 No recent reports of development identified for phase-I development in Solid-tumours(Combination therapy, Metastatic disease, Second-line therapy or greater) in USA (SC, Injection)
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top